Sequence Bio runs a population-scale clinico-genomic study of inherited disease in Newfoundland with NL Health Services.
Competing Products
Sequence Bioinformatics
Revolutionizing drug discovery with Newfoundland founder effect.
Revolutionizing drug discovery with Newfoundland founder effect.
Sequence Bio, founded with the mission to revolutionize drug discovery, leverages the unique genetic makeup of Newfoundland's population to identify true signals of disease. Their core vision is to enhance the success rate of drug candidates, which currently see a 90% failure rate, thereby expediting the development of life-changing medications. Sequence Bio focuses on better drug target discovery through genomic research and data analysis, aiming to provide more effective treatments for patients in need.
Notable figures associated with Sequence Bio include experts in genomics and pharmaceutical development, although specific names are not provided. The company has garnered attention from investors interested in innovative healthcare solutions. Key achievements include significant advancements in understanding genetic markers linked to diseases, contributing to the broader field of precision medicine. Sequence Bio's impact lies in its potential to transform drug development processes, ultimately improving patient outcomes and reducing the time and cost associated with bringing new drugs to market.
Companies similar to Sequence Bioinformatics include UK Biobank, Helix, Variant Bio and Recursion Pharmaceuticals.
Sequence Bioinformatics was founded in 2013.
Sequence Bioinformatics' headquarters is located in St. John's, Newfoundland and Labrador, CA.
As of May 20, 2021, Sequence Bioinformatics has disclosed funding of $150k (USD). Undisclosed round amounts are excluded.
Sequence Bioinformatics has 75 employees as of Feb 24, 2024.
Recursion Pharmaceuticals
recursion.com